AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28818998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) during -12° head-down tilt (HDT)
Number of subjects: 9
Study 28818998 — intervention group
Group type: COMPARATOR
Intervention: -6° head-down tilt (HDT)
Number of subjects: 9
Study 28818998 — intervention group
Group type: COMPARATOR
Intervention: -12° head-down tilt (HDT)
Number of subjects: 9
Study 28818998 — intervention group
Group type: COMPARATOR
Intervention: -18° head-down tilt (HDT)
Number of subjects: 9
Study 28818998 — intervention group
Group type: COMPARATOR
Intervention: -12° head-down tilt with 1% CO2
Number of subjects: 9
Study 25327872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of double‐balloon catheter and oral misoprostol
Number of subjects: 326
Study 25327872 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 326
Study 23388346 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding (BF)
Number of subjects: 91
Study 23388346 — intervention group
Group type: COMPARATOR
Intervention: Standard control formula
Number of subjects: 91
Study 23388346 — intervention group
Group type: COMPARATOR
Intervention: High-sn-2 palmitate formula
Number of subjects: 91
Study 21067880 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine concentration of 370 mg I/mL (Group B)
Number of subjects: 105
Study 21067880 — intervention group
Group type: COMPARATOR
Intervention: Iodine concentration of 300 mg I/mL (Group A)
Number of subjects: 105
Study 19308807 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on intraprostatic BoNT‐A injection (200-600 U of Botox)
Number of subjects: 60
Study 19308807 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy (control group)
Number of subjects: 60
Study 17350966 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years basic parenting programme, a 12 week group based intervention
Number of subjects: 153
Study 17350966 — intervention group
Group type: COMPARATOR
Intervention: Wait listing (control)
Number of subjects: 153
Study 17350966 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years basic parenting programme
Number of subjects: 153
Study 15452006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ads incorporating a prescription drug benefit box
Number of subjects: 0
Study 15452006 — intervention group
Group type: COMPARATOR
Intervention: Ads without a prescription drug benefit box
Number of subjects: 0
Study 15452006 — intervention group
Group type: EXPERIMENTAL
Intervention: General perception of benefit data in drug ads
Number of subjects: 0
Study 11552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a 2.5 cm shoe-lift
Number of subjects: 8
Study 11552869 — intervention group
Group type: COMPARATOR
Intervention: Walking without a shoe-lift
Number of subjects: 8
Study 9013360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel syndrome patients (CTS)
Number of subjects: 26
Study 9013360 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 26
Study 7833515 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 40
Study 7833515 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 40
Study 2971182 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740
Number of subjects: 0
Study 2971182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30309327 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI) 0.6 mL/kg administered intravenously from the time of anesthesia induction to the beginning of CPB.
Number of subjects: 88
Study 30309327 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 88
Study 29349214 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) program
Number of subjects: 0
Study 25892174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 43
Study 25892174 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth coping and therapist interventions
Number of subjects: 43
Study 25892174 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-interfering behavior
Number of subjects: 43
Study 25892174 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-interfering behaviors
Number of subjects: 43
Study 25892174 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth coping
Number of subjects: 43
Study 23368948 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG)
Number of subjects: 36
Study 23368948 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus resin-modified glass ionomer restoration (CTG+R)
Number of subjects: 36
Study 21601343 — intervention group
Group type: EXPERIMENTAL
Intervention: CRQ-SAS (self-administered version)
Number of subjects: 40
Study 21601343 — intervention group
Group type: COMPARATOR
Intervention: CRQ-IA (interviewer-administered version)
Number of subjects: 40
Study 18468272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BTX‐A)
Number of subjects: 20
Study 18468272 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 20
Study 16820551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g daily)
Number of subjects: 145
Study 16820551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 14674906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 8
Study 14674906 — intervention group
Group type: COMPARATOR
Intervention: Control period (no charcoal taken)
Number of subjects: 8
Study 10791245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus‐preserving gastrectomy
Number of subjects: 50
Study 10791245 — intervention group
Group type: COMPARATOR
Intervention: Distal gastrectomy with Billroth I anastomosis
Number of subjects: 50
Study 8677191 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 28
Study 8677191 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 healthy volunteers)
Number of subjects: 28
Study 1803767 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant influenza vaccine
Number of subjects: 0
Study 1803767 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 1803767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6096154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 12
Study 6096154 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg/day)
Number of subjects: 12
Study 29370813 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems consultation intervention
Number of subjects: 8
Study 29370813 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 8
Study 27756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW) online platform for mental health self-management and peer support for 3 months
Number of subjects: 0
Study 27756281 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW) online platform for mental health self-management and peer support for an additional 3 months (opt-in extension)
Number of subjects: 0
Study 27756281 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (opt-in extension control)
Number of subjects: 0
Study 24855368 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg
Number of subjects: 0
Study 24855368 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMVA 10, 20, or 40 mg
Number of subjects: 0
Study 24855368 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg + SIMVA (10, 20, or 40 mg)
Number of subjects: 0
Study 24855368 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (baseline)
Number of subjects: 0
Study 24165325 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural tool
Number of subjects: 20
Study 20003924 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 182
Study 20003924 — intervention group
Group type: COMPARATOR
Intervention: No influenza vaccination (Control)
Number of subjects: 182
Study 18831744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg (two 40 mg injections at baseline followed by one 40 mg injection every other week from Week 1 to Week 15)
Number of subjects: 1205
Study 18831744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 1205
Study 18831744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1205
Study 15971040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern A edema (found in 28 patients, 9.8%)
Number of subjects: 285
Study 15971040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern B edema (found in 10 patients, 3.5%)
Number of subjects: 285
Study 15971040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver study (20 cadavers)
Number of subjects: 285
Study 12944570 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg of everolimus per day
Number of subjects: 634
Study 12944570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of everolimus per day
Number of subjects: 634
Study 12944570 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (1.0 to 3.0 mg per kg per day)
Number of subjects: 634
Study 10944065 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomysium antibodies
Number of subjects: 1260
Study 10944065 — intervention group
Group type: COMPARATOR
Intervention: IgA-gluten antibodies
Number of subjects: 1260
Study 10944065 — intervention group
Group type: COMPARATOR
Intervention: IgG-gluten antibodies
Number of subjects: 1260
Study 8937483 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (CDDP 16 mg/m2 for 5 days with 5-FU 700 mg/m2/day for 5 days)
Number of subjects: 42
Study 8937483 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (CDDP 80 mg on day 1 with 5-FU 700 mg/m2/day for 5 days)
Number of subjects: 42
Study 8937483 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT adjuvant chemotherapy (600 mg/day from day 1 to day 14) with CBDCA (350 mg/m2 on day 7)
Number of subjects: 42
Study 1587073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine plus phentermine (60 mg fenfluramine plus 30 mg phentermine)
Number of subjects: 83
Study 1587073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine plus phentermine (continued therapy)
Number of subjects: 83
Study 1587073 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intermittent therapy
Number of subjects: 83
Study 1587073 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy
Number of subjects: 83
Study 1587073 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight loss (all participants)
Number of subjects: 83
Study 2858708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) 50 mg 3 times a week for 3 consecutive weeks
Number of subjects: 41
Study 2858708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 30346511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 158
Study 30346511 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-containing ART (after HIV-1 acquisition)
Number of subjects: 158
Study 29492613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol in a vodka and tonic-mixed drink
Number of subjects: 54
Study 29492613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tonic with 4 ml of vodka sprayed on top)
Number of subjects: 54
Study 27869096 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-Gy involved-field radiation therapy (IFRT)
Number of subjects: 716
Study 27869096 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 716
Study 25086593 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month physical exercise training programme including exercise training, resistance training, breathing exercises, and advice on increasing physical activity
Number of subjects: 102
Study 25086593 — intervention group
Group type: COMPARATOR
Intervention: Usual care with advice on increasing physical activity and a sham treatment
Number of subjects: 102
Study 23714670 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI plus DEX (DEX:EPI = 10:1)
Number of subjects: 122
Study 23714670 — intervention group
Group type: COMPARATOR
Intervention: EPI
Number of subjects: 122
Study 20637390 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol (200 mg) with piroxicam (20 mg)
Number of subjects: 253
Study 20637390 — intervention group
Group type: COMPARATOR
Intervention: Placebo with piroxicam (20 mg)
Number of subjects: 253
Study 19107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealing of 1 maxillary first molar and 1 mandibular first molar
Number of subjects: 360
Study 19107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealing of all first molars
Number of subjects: 360
Study 19107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealing of all molars and premolars on eruption
Number of subjects: 360
Study 19107268 — intervention group
Group type: COMPARATOR
Intervention: No teeth sealed (control group)
Number of subjects: 360
Study 16834644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg once daily
Number of subjects: 77
Study 16834644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg three times daily
Number of subjects: 77
Study 16834644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily
Number of subjects: 77
Study 16834644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 16834644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 45 mg
Number of subjects: 77
Study 16834644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg
Number of subjects: 77
Study 12907830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Number of subjects: 25
Study 12907830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate complex (FerroSanol, Schwarz, Germany) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Number of subjects: 25
Study 11003764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (n = 167)
Number of subjects: 330
Study 11003764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 163)
Number of subjects: 330
Study 8975951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 300 mg orally twice a day
Number of subjects: 59
Study 8975951 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally BID
Number of subjects: 59
Study 8975951 — intervention group
Group type: COMPARATOR
Intervention: Untreated medical control group
Number of subjects: 59
Study 1477017 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (up to 600 mg daily)
Number of subjects: 144
Study 1477017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 1477017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (early-onset group)
Number of subjects: 144
Study 4003495 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 10
Study 4003495 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eyedrops with concomitant indomethacin
Number of subjects: 10
Study 31324181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornelian cherry extract (320 mg/day of anthocyanins) for 12 weeks
Number of subjects: 80
Study 31324181 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 80
Study 29446471 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified technique (SG)
Number of subjects: 40
Study 29446471 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (CG)
Number of subjects: 40
Study 27555136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block (CFSNB)
Number of subjects: 68
Study 27555136 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 68
Study 24687251 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol/normal saline
Number of subjects: 56
Study 24687251 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and normal saline
Number of subjects: 56
Study 24687251 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus magnesium sulfate
Number of subjects: 56
Study 24687251 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 56
Study 22980596 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic rubber band ligation (EBL) using Saeed multiband ligator
Number of subjects: 120
Study 22980596 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS) using either ethanolamine oleate 5% or N‐butyl cyanoacrylate
Number of subjects: 120
Study 20029189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.)
Number of subjects: 50
Study 20029189 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicergoline)
Number of subjects: 50
Study 20029189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.) in patients with bilateral basal ganglia involvement
Number of subjects: 50
Study 20029189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.) in patients with no or unilateral basal ganglia involvement
Number of subjects: 50
Study 17823084 — intervention group
Group type: COMPARATOR
Intervention: Exercise hyperthermia (E) - subjects exercised for two hours on a treadmill at 65% max in thermoneutral conditions, followed by 1-h recovery in thermoneutral conditions.
Number of subjects: 8
Study 17823084 — intervention group
Group type: COMPARATOR
Intervention: Passive hyperthermia (PH) - subjects remained in a semi-recumbent position in a climatic chamber for two hours in hot conditions, followed by 1-h recovery in thermoneutral conditions.
Number of subjects: 8
Study 17823084 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (C) - subjects remained in a sitting posture for three hours in thermoneutral conditions.
Number of subjects: 8
Study 18720219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial encoding effects induced by the DRM task
Number of subjects: 0
Study 18720219 — intervention group
Group type: EXPERIMENTAL
Intervention: List-specific cues during encoding
Number of subjects: 0
Study 15099665 — intervention group
Group type: EXPERIMENTAL
Intervention: Format A (questions on quantity and frequency of alcohol consumption first)
Number of subjects: 1213
Study 15099665 — intervention group
Group type: COMPARATOR
Intervention: Format B (CAGE questions first)
Number of subjects: 1213
Study 11298066 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone with efavirenz
Number of subjects: 11
Study 9396885 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 103
Study 9396885 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (dinoprostone) 3 mg
Number of subjects: 103
Study 8186906 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bimesylate (AB) 50-100 mg/day
Number of subjects: 21
Study 8186906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8186906 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bimesylate (AB)
Number of subjects: 21
Study 3073869 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU/m2 human lymphoblastoid interferon (Wellferon), three times weekly for 6 months
Number of subjects: 25
Study 3073869 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 29065815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-oxidative ozone therapy (OG, n = 20)
Number of subjects: 40
Study 29065815 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splints (OCSG, n = 20)
Number of subjects: 40
Study 29026111 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 16
Study 29026111 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Suppression
Number of subjects: 16
Study 26900599 — intervention group
Group type: EXPERIMENTAL
Intervention: SunProtect™ program with text message reminders
Number of subjects: 170
Study 26900599 — intervention group
Group type: COMPARATOR
Intervention: Usual education (Control)
Number of subjects: 170
Study 24433640 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.15 mmol/kg)
Number of subjects: 12
Study 24433640 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA (0.2 mmol/kg)
Number of subjects: 12
Study 21830011 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tent (3 mm intracervical)
Number of subjects: 70
Study 21830011 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (400 μg vaginal)
Number of subjects: 70
Study 19996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted endothelial keratoplasty (FLEK)
Number of subjects: 80
Study 19996929 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 80
Study 17476291 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 8243
Study 15699480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 602
Study 15699480 — intervention group
Group type: COMPARATOR
Intervention: Coumarin derivative
Number of subjects: 602
Study 15699480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin vs Coumarin derivatives
Number of subjects: 602
Study 11981594 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day sertraline
Number of subjects: 295
Study 11981594 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day sertraline plus 30 mg/day mianserin
Number of subjects: 295
Study 11981594 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day sertraline
Number of subjects: 295
Study 9549822 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal quality of life measurements
Number of subjects: 0
Study 7876651 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections on day 0
Number of subjects: 276
Study 7876651 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection on day 0 and 14
Number of subjects: 276